Do analysts prefer FEMY or SONX?

Femasys presently has a consensus price target of $106.67, indicating a potential upside of 2,457.95%. Given Femasys' stronger consensus rating and higher possible upside, equities analysts clearly believe Femasys is more favorable than Sonendo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, FEMY or SONX?

Femasys has higher earnings, but lower revenue than Sonendo. Femasys is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.29M 5.50 -$18.63M -$5.40 N/A Sonendo $44.40M 0.06 -$60.92M -$71.12 N/A

Is FEMY or SONX more profitable?

Sonendo has a net margin of -92.74% compared to Femasys' net margin of -521.97%. Sonendo's return on equity of -184.01% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -521.97% -258.08% -73.72% Sonendo -92.74% -184.01% -68.60%

Do analysts prefer SURG or SONX?

SurgePays currently has a consensus price target of $3.50, indicating a potential upside of 510.93%. Given SurgePays' stronger consensus rating and higher possible upside, equities research analysts plainly believe SurgePays is more favorable than Sonendo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SurgePays 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, SURG or SONX?

SurgePays has higher revenue and earnings than Sonendo. SurgePays is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SurgePays $56.96M 0.25 -$36.07M -$1.94 N/A Sonendo $44.40M 0.06 -$60.92M -$71.12 N/A

Is SURG or SONX more profitable?

SurgePays has a net margin of -64.91% compared to Sonendo's net margin of -92.74%. SurgePays' return on equity of 0.00% beat Sonendo's return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% N/A -310.16% Sonendo -92.74% -184.01% -68.60%

Do analysts recommend SONX or MBAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SONX or MBAI more profitable?

Check-Cap has a net margin of 0.00% compared to Sonendo's net margin of -92.74%. Check-Cap's return on equity of 0.00% beat Sonendo's return on equity. Company Net Margins Return on Equity Return on Assets Sonendo -92.74% -184.01% -68.60% Check-Cap N/A N/A N/A

Do analysts recommend ALUR or SONX?

Allurion Technologies presently has a consensus price target of $45.00, indicating a potential upside of 7,658.62%. Given Allurion Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe Allurion Technologies is more favorable than Sonendo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allurion Technologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend SINT or SONX?

Sintx Technologies presently has a consensus price target of $9.33, suggesting a potential upside of 391.23%. Given Sintx Technologies' stronger consensus rating and higher probable upside, research analysts clearly believe Sintx Technologies is more favorable than Sonendo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sintx Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is SINT or SONX more profitable?

Sonendo has a net margin of -92.74% compared to Sintx Technologies' net margin of -1,058.60%. Sonendo's return on equity of -184.01% beat Sintx Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Sintx Technologies -1,058.60% -366.49% -115.04% Sonendo -92.74% -184.01% -68.60%

Sonendo (SONX) Competitors

$0.60 0.00 (0.00%)

As of 07/2/2026

Compare

SONX vs. FEMY, SURG, MBAI, ALUR, and SINT

Should you buy Sonendo stock or one of its competitors? MarketBeat compares Sonendo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sonendo include Femasys (FEMY), SurgePays (SURG), Check-Cap (MBAI), Allurion Technologies (ALUR), and Sintx Technologies (SINT). These companies are all part of the "medical equipment" industry.

How does Sonendo compare to Femasys?

Femasys (NASDAQ:FEMY) and Sonendo (NYSE:SONX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Femasys has a beta of -2.13, meaning that its stock price is 313% less volatile than the broader market. Comparatively, Sonendo has a beta of 2.01, meaning that its stock price is 101% more volatile than the broader market.

Femasys has higher earnings, but lower revenue than Sonendo. Femasys is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	5.50	-$18.63M	-$5.40	N/A
Sonendo	$44.40M	0.06	-$60.92M	-$71.12	N/A

65.3% of Femasys shares are held by institutional investors. Comparatively, 28.7% of Sonendo shares are held by institutional investors. 7.8% of Femasys shares are held by company insiders. Comparatively, 7.9% of Sonendo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Femasys' average media sentiment score of 0.00 equaled Sonendo'saverage media sentiment score.

Company	Overall Sentiment
Femasys	Neutral
Sonendo	Neutral

Femasys presently has a consensus price target of $106.67, indicating a potential upside of 2,457.95%. Given Femasys' stronger consensus rating and higher possible upside, equities analysts clearly believe Femasys is more favorable than Sonendo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Sonendo has a net margin of -92.74% compared to Femasys' net margin of -521.97%. Sonendo's return on equity of -184.01% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
Sonendo	-92.74%	-184.01%	-68.60%

Summary

Femasys and Sonendo tied by winning 7 of the 14 factors compared between the two stocks.

How does Sonendo compare to SurgePays?

SurgePays (NASDAQ:SURG) and Sonendo (NYSE:SONX) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

SurgePays has higher revenue and earnings than Sonendo. SurgePays is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.25	-$36.07M	-$1.94	N/A
Sonendo	$44.40M	0.06	-$60.92M	-$71.12	N/A

SurgePays has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Sonendo has a beta of 2.01, meaning that its stock price is 101% more volatile than the broader market.

SurgePays has a net margin of -64.91% compared to Sonendo's net margin of -92.74%. SurgePays' return on equity of 0.00% beat Sonendo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	N/A	-310.16%
Sonendo	-92.74%	-184.01%	-68.60%

SurgePays currently has a consensus price target of $3.50, indicating a potential upside of 510.93%. Given SurgePays' stronger consensus rating and higher possible upside, equities research analysts plainly believe SurgePays is more favorable than Sonendo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, SurgePays had 4 more articles in the media than Sonendo. MarketBeat recorded 4 mentions for SurgePays and 0 mentions for Sonendo. SurgePays' average media sentiment score of 0.25 beat Sonendo's score of 0.00 indicating that SurgePays is being referred to more favorably in the media.

Company	Overall Sentiment
SurgePays	Neutral
Sonendo	Neutral

6.9% of SurgePays shares are held by institutional investors. Comparatively, 28.7% of Sonendo shares are held by institutional investors. 29.1% of SurgePays shares are held by insiders. Comparatively, 7.9% of Sonendo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

SurgePays beats Sonendo on 12 of the 16 factors compared between the two stocks.

How does Sonendo compare to Check-Cap?

Sonendo (NYSE:SONX) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Sonendo has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

Check-Cap has a net margin of 0.00% compared to Sonendo's net margin of -92.74%. Check-Cap's return on equity of 0.00% beat Sonendo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonendo	-92.74%	-184.01%	-68.60%
Check-Cap	N/A	N/A	N/A

Check-Cap has lower revenue, but higher earnings than Sonendo. Check-Cap is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonendo	$44.40M	0.06	-$60.92M	-$71.12	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A

In the previous week, Check-Cap had 1 more articles in the media than Sonendo. MarketBeat recorded 1 mentions for Check-Cap and 0 mentions for Sonendo. Check-Cap's average media sentiment score of 0.21 beat Sonendo's score of 0.00 indicating that Check-Cap is being referred to more favorably in the news media.

Company	Overall Sentiment
Sonendo	Neutral
Check-Cap	Neutral

28.7% of Sonendo shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 7.9% of Sonendo shares are held by company insiders. Comparatively, 0.5% of Check-Cap shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Check-Cap beats Sonendo on 8 of the 13 factors compared between the two stocks.

How does Sonendo compare to Allurion Technologies?

Allurion Technologies (NYSE:ALUR) and Sonendo (NYSE:SONX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Allurion Technologies presently has a consensus price target of $45.00, indicating a potential upside of 7,658.62%. Given Allurion Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe Allurion Technologies is more favorable than Sonendo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

21.4% of Allurion Technologies shares are held by institutional investors. Comparatively, 28.7% of Sonendo shares are held by institutional investors. 8.1% of Allurion Technologies shares are held by insiders. Comparatively, 7.9% of Sonendo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Allurion Technologies has a beta of -0.13, indicating that its stock price is 113% less volatile than the broader market. Comparatively, Sonendo has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market.

In the previous week, Allurion Technologies had 2 more articles in the media than Sonendo. MarketBeat recorded 2 mentions for Allurion Technologies and 0 mentions for Sonendo. Sonendo's average media sentiment score of 0.00 beat Allurion Technologies' score of -0.36 indicating that Sonendo is being referred to more favorably in the news media.

Company	Overall Sentiment
Allurion Technologies	Neutral
Sonendo	Neutral

Allurion Technologies has higher earnings, but lower revenue than Sonendo. Allurion Technologies is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$17.21M	0.51	-$7.20M	-$2.03	N/A
Sonendo	$44.40M	0.06	-$60.92M	-$71.12	N/A

Sonendo has a net margin of -92.74% compared to Allurion Technologies' net margin of -199.96%. Allurion Technologies' return on equity of 0.00% beat Sonendo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-199.96%	N/A	-77.13%
Sonendo	-92.74%	-184.01%	-68.60%

Summary

Allurion Technologies beats Sonendo on 9 of the 16 factors compared between the two stocks.

How does Sonendo compare to Sintx Technologies?

Sintx Technologies (NASDAQ:SINT) and Sonendo (NYSE:SONX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Sintx Technologies has higher earnings, but lower revenue than Sonendo. Sintx Technologies is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$1.02M	8.05	-$10.36M	-$5.07	N/A
Sonendo	$44.40M	0.06	-$60.92M	-$71.12	N/A

Sintx Technologies has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Sonendo has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market.

Sintx Technologies presently has a consensus price target of $9.33, suggesting a potential upside of 391.23%. Given Sintx Technologies' stronger consensus rating and higher probable upside, research analysts clearly believe Sintx Technologies is more favorable than Sonendo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Sonendo has a net margin of -92.74% compared to Sintx Technologies' net margin of -1,058.60%. Sonendo's return on equity of -184.01% beat Sintx Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-1,058.60%	-366.49%	-115.04%
Sonendo	-92.74%	-184.01%	-68.60%

18.4% of Sintx Technologies shares are owned by institutional investors. Comparatively, 28.7% of Sonendo shares are owned by institutional investors. 4.1% of Sintx Technologies shares are owned by company insiders. Comparatively, 7.9% of Sonendo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Sintx Technologies' average media sentiment score of 0.00 equaled Sonendo'saverage media sentiment score.

Company	Overall Sentiment
Sintx Technologies	Neutral
Sonendo	Neutral

Summary

Sonendo beats Sintx Technologies on 8 of the 14 factors compared between the two stocks.

Get Sonendo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SONX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SONX vs. The Competition

Export

Metric	Sonendo	Dental equipment & supplies Industry	Medical Sector	NYSE Exchange
Market Cap	$2.87M	$2.87M	$7.16B	$23.53B
Dividend Yield	N/A	N/A	2.66%	3.98%
P/E Ratio	-0.01	N/A	28.02	31.55
Price / Sales	0.06	0.06	540.55	21.06
Price / Cash	N/A	N/A	49.26	25.36
Price / Book	0.01	0.01	10.96	4.81
Net Income	-$60.92M	-$60.92M	$3.57B	$1.07B
7 Day Performance	N/A	N/A	2.12%	0.56%
1 Month Performance	N/A	N/A	5.25%	4.54%
1 Year Performance	N/A	-47.83%	33.29%	18.23%

Sonendo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SONX Sonendo	N/A	$0.60 flat	N/A	N/A	$2.87M	$44.40M	N/A	250
FEMY Femasys	1.9724 of 5 stars	$3.60 -1.9%	$106.67 +2,863.0%	-77.7%	$11.08M	$2.29M	N/A	30	Gap Up
SURG SurgePays	3.69 of 5 stars	$0.38 -3.1%	$3.50 +821.1%	-82.2%	$9.85M	$56.96M	N/A	40	News Coverage
MBAI Check-Cap	0.3201 of 5 stars	$1.11 -14.0%	N/A	N/A	$9.40M	N/A	N/A	80	Short Interest Increase
ALUR Allurion Technologies	1.4578 of 5 stars	$0.58 flat	$45.00 +7,658.6%	-98.5%	$8.70M	$17.21M	N/A	501

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SONX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sonendo (SONX) Competitors